QYUNS-B(02509),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02509 QYUNS-B

Market Closed 04-24 16:08:27

18.010

-0.040

-0.22%

High18.600	Low17.720	Vol197.65K
Open18.070	D1 Closing18.050	Amplitude4.88%
Mkt Cap4.05B	Tradable Cap4.05B	Total Shares225.00M
T/O3.59M	T/O Rate0.09%	Tradable Shares225.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02509","market":"HK","secType":"STK","nameCN":"QYUNS-B","latestPrice":18.01,"timestamp":1777018107005,"preClose":18.05,"halted":0,"volume":197650,"delay":0,"changeRate":-0.0022160664819944123,"floatShares":225000000,"shares":225000000,"eps":1.6161097268581635,"marketStatus":"Market Closed","change":-0.04,"latestTime":"04-24 16:08:27","open":18.07,"high":18.6,"low":17.72,"amount":3592797,"amplitude":0.048753,"askPrice":18.4,"askSize":18000,"bidPrice":17.97,"bidSize":1200,"shortable":3,"etf":0,"ttmEps":1.6161097268581635,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1777253400000},"marketStatusCode":7,"adr":0,"listingDate":1710864000000,"exchange":"SEHK","adjPreClose":18.05,"openAndCloseTimeList":[[1776994200000,1777003200000],[1777006800000,1777017600000]],"volumeRatio":0.5637478610351531,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02509/tweets","defaultTab":"tweets","newsList":[{"id":"1137432614","title":"QYUNS-B Shares Surge Over 8% Following Turn to Profit Last Year; Projected Sales of Key Product Near RMB 500 Million This Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1137432614","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137432614?lang=en_us&edition=fundamental","pubTime":"2026-04-15 10:56","pubTimestamp":1776221806,"startTime":"0","endTime":"0","summary":"QYUNS-B (02509) rose more than 8% during the trading session. At the time of writing, the stock was up 7.22% to HK$20.78, with a turnover of HK$10.18 million. The company's 2025 results showed...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4531","BK4588","LU1235295612.USD","VXUS","LU1046422090.SGD","02509","BK4585","BK1161","BK4166","BK4579","LX","LU0049112450.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179832135","title":"QYUNS-B Reports Stable Share Capital and Confirms Public Float Compliance for March 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1179832135","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179832135?lang=en_us&edition=fundamental","pubTime":"2026-04-09 18:48","pubTimestamp":1775731680,"startTime":"0","endTime":"0","summary":"Qyuns Therapeutics Co., Ltd. (QYUNS-B) submitted its Monthly Return for Equity Issuer to Hong Kong Exchanges and Clearing Limited on 9 April 2026, covering the month ended 31 March 2026. The...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624205698","title":"Shareholders Will Be Pleased With The Quality of Qyuns Therapeutics' (HKG:2509) Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2624205698","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624205698?lang=en_us&edition=fundamental","pubTime":"2026-04-04 06:40","pubTimestamp":1775256021,"startTime":"0","endTime":"0","summary":"Qyuns Therapeutics Co., Ltd. ( HKG:2509 ) just reported healthy earnings but the stock price didn't move much. We think...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2509/qyuns-therapeutics-shares/news/shareholders-will-be-pleased-with-the-quality-of-qyuns-thera","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2509/qyuns-therapeutics-shares/news/shareholders-will-be-pleased-with-the-quality-of-qyuns-thera","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["02509","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622876838","title":"Qyuns Therapeutics Forms Strategy and Development Committee to Sharpen Long-Term Planning","url":"https://stock-news.laohu8.com/highlight/detail?id=2622876838","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622876838?lang=en_us&edition=fundamental","pubTime":"2026-03-27 23:22","pubTimestamp":1774624927,"startTime":"0","endTime":"0","summary":"Qyuns Therapeutics Co., Ltd. Class H ( ($HK:2509) ) just unveiled an update. Qyuns Therapeutics has created a Strategy and Development Committee un...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/qyuns-therapeutics-forms-strategy-and-development-committee-to-sharpen-long-term-planning?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/qyuns-therapeutics-forms-strategy-and-development-committee-to-sharpen-long-term-planning?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MSST","MSTW","APED","SMST","MSTY","BK4600","BK4595","MSTP","BK4588","BK4139","SMI3.UK","09799","09399","02509","MSDD","MST","WNTR","BK4516","MTYY","MSTY.UK","LMI3.UK","MSTK","07399","3SMI.UK","MSII","BK4007","MSOO","BK4596","MSTZ","BK4023","BK4585","IMST","BK4539","MSTX","3LMI.UK","07799"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179351235","title":"QYUNS-B Reports Over 400% Revenue Surge in 2025, Swings to Adjusted Profit of 356 Million Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=1179351235","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179351235?lang=en_us&edition=fundamental","pubTime":"2026-03-27 21:09","pubTimestamp":1774616942,"startTime":"0","endTime":"0","summary":"QYUNS-B (02509) announced its 2025 financial results, reporting revenue of approximately 807 million yuan, an increase of about 4.08 times year-over-year. Gross profit reached about 714 million yuan,...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622821910","title":"Qyuns Therapeutics - FY Revenue RMB807 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2622821910","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622821910?lang=en_us&edition=fundamental","pubTime":"2026-03-27 20:46","pubTimestamp":1774615581,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nFWN40F0PK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621053696","title":"Qyuns Therapeutics Invests 100 Million Yuan in Wealth Management Product","url":"https://stock-news.laohu8.com/highlight/detail?id=2621053696","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621053696?lang=en_us&edition=fundamental","pubTime":"2026-03-24 13:40","pubTimestamp":1774330813,"startTime":"0","endTime":"0","summary":"Qyuns Therapeutics  said it invested 100 million yuan in a wealth management product offered by Shanghai Pudong Development Bank, according to a Hong Kong bourse filing Monday.Shares of the biopharmaceutical company gained over 3% in afternoon trade Tuesday.The product matures Sept. 23 and offers a guaranteed yield of 0.95% and a floating yield of 0% or 1.05% in the mid range or 1.25% in the high range.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02509","LENZ","BK1161","BK4139","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621922707","title":"BRIEF-Qyuns Therapeutics Co To Subscribe For PDB Wealth Management Product With RMB100 Million Principal","url":"https://stock-news.laohu8.com/highlight/detail?id=2621922707","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621922707?lang=en_us&edition=fundamental","pubTime":"2026-03-23 23:21","pubTimestamp":1774279285,"startTime":"0","endTime":"0","summary":"BRIEF-Qyuns Therapeutics Co To Subscribe For PDB Wealth Management Product With RMB100 Million PrincipalMarch 23  - Qyuns Therapeutics Co Ltd 2509.HK:TO SUBSCRIBE FOR PDB WEALTH MANAGEMENT PRODUCT WITH RMB100 MILLION PRINCIPALFurther company coverage: 2509.HK ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nFWN40B0T2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140999385","title":"QYUNS-B (02509) Invests 100 Million Yuan in Wealth Management Product","url":"https://stock-news.laohu8.com/highlight/detail?id=1140999385","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1140999385?lang=en_us&edition=fundamental","pubTime":"2026-03-23 22:18","pubTimestamp":1774275495,"startTime":"0","endTime":"0","summary":"QYUNS-B (02509) announced that on March 23, 2026, the company entered into a subscription agreement with SPD Bank to purchase a wealth management product. The move is aimed at efficiently utilizing...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621701610","title":"Qyuns Therapeutics Co Ltd - to Subscribe for Pdb Wealth Management Product With RMB100 Mln Principal","url":"https://stock-news.laohu8.com/highlight/detail?id=2621701610","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621701610?lang=en_us&edition=fundamental","pubTime":"2026-03-23 21:59","pubTimestamp":1774274355,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nFWN40B0T2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111183599","title":"GTHT Securities Initiates Coverage on QYUNS-B with \"Buy\" Rating, Highlights Focus on Autoimmune Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=1111183599","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111183599?lang=en_us&edition=fundamental","pubTime":"2026-03-12 09:26","pubTimestamp":1773278789,"startTime":"0","endTime":"0","summary":"GTHT Securities has issued a research report initiating coverage on QYUNS-B (02509) with a \"Buy\" rating. The company concentrates on developing biologic therapies for autoimmune and allergic...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1564","BK1147","161027","02509","02611"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618884289","title":"Qyuns Therapeutics' Arthritis Drug Crusekitug Accepted for Review in China; Shares Jump 11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618884289","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618884289?lang=en_us&edition=fundamental","pubTime":"2026-03-10 12:30","pubTimestamp":1773117006,"startTime":"0","endTime":"0","summary":"Qyuns Therapeutics (HKG:2509) said its injectable spinal arthritis drug, crusekitug, was accepted for review in China, according to a Hong Kong bourse filing Monday.Shares of the biopharmaceutical firm were up over 11% in late morning trade Tuesday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02509","BK4007","BK4139","BK1161","BK4539","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618947620","title":"BRIEF-Qyuns Therapeutics Says New Drug Application Of Crusekitug (Qx002n) Accepted By NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2618947620","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618947620?lang=en_us&edition=fundamental","pubTime":"2026-03-09 23:33","pubTimestamp":1773070401,"startTime":"0","endTime":"0","summary":"BRIEF-Qyuns Therapeutics Says New Drug Application Of Crusekitug  Accepted By NMPAMarch 9  - Qyuns Therapeutics Co Ltd 2509.HK:NEW DRUG APPLICATION OF CRUSEKITUG  FOR TREATMENT OF ACTIVE ANKYLOSING SPONDYLITIS IN ADULTS ACCEPTED BY NMPAFurther company coverage: 2509.HK ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nFWN3ZX1BF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174716224","title":"QYUNS-B (02509) Gains NMPA Acceptance for Lusekizumab (QX002N) New Drug Application Targeting Active Ankylosing Spondylitis in Adults","url":"https://stock-news.laohu8.com/highlight/detail?id=1174716224","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174716224?lang=en_us&edition=fundamental","pubTime":"2026-03-09 22:07","pubTimestamp":1773065274,"startTime":"0","endTime":"0","summary":"QYUNS-B (02509) announced that the New Drug Application for its self-developed Lusekizumab injection (an anti-IL-17A monoclonal antibody, R&D code: QX002N) was accepted by the National Medical...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618624990","title":"Qyuns Therapeutics’ Crusekitug NDA for adult ankylosing spondylitis accepted by China’s NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2618624990","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618624990?lang=en_us&edition=fundamental","pubTime":"2026-03-09 22:01","pubTimestamp":1773064881,"startTime":"0","endTime":"0","summary":"Qyuns Therapeutics said China’s National Medical Products Administration accepted its new drug application for Crusekitug  to treat active ankylosing spondylitis in adults. The application is supported by a Phase III trial  that reported 52-week efficacy and safety results.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qyuns Therapeutics Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 09, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nNDL1W572Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618992624","title":"Qyuns Therapeutics Co Ltd - New Drug Application of Crusekitug (QX002n) for Treatment of Active Ankylosing Spondylitis in Adults Accepted by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2618992624","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618992624?lang=en_us&edition=fundamental","pubTime":"2026-03-09 22:01","pubTimestamp":1773064878,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nFWN3ZX1BF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02509","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172684046","title":"QYUNS-B (02509) Announces Monthly Return for February 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1172684046","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172684046?lang=en_us&edition=fundamental","pubTime":"2026-03-05 17:34","pubTimestamp":1772703273,"startTime":"0","endTime":"0","summary":"Qyuns Therapeutics Co., Ltd. reported that, as of 28 February 2026, its authorized share capital remained at 227.07 million shares with a par value of RMB 1, totaling RMB 227.07 million. Issued...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133624375","title":"Qyuns Therapeutics (02509) Announces Latest Share Repurchase Update","url":"https://stock-news.laohu8.com/highlight/detail?id=1133624375","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133624375?lang=en_us&edition=fundamental","pubTime":"2026-02-06 19:42","pubTimestamp":1770378150,"startTime":"0","endTime":"0","summary":"Qyuns Therapeutics Co., Ltd. (02509) disclosed a share repurchase conducted on 06 February 2026. The company repurchased 16,200 H shares on the Hong Kong Stock Exchange at a highest price of HKD...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120130000","title":"QYUNS-B Repurchases 16,200 Shares for HK$326,000 on February 6","url":"https://stock-news.laohu8.com/highlight/detail?id=1120130000","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120130000?lang=en_us&edition=fundamental","pubTime":"2026-02-06 19:29","pubTimestamp":1770377349,"startTime":"0","endTime":"0","summary":"QYUNS-B (02509) announced that on February 6, 2026, the company repurchased 16,200 shares at a total cost of approximately HK$326,000.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133225317","title":"Qyuns Therapeutics (2509) Announces On-Market Share Repurchase Update","url":"https://stock-news.laohu8.com/highlight/detail?id=1133225317","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133225317?lang=en_us&edition=fundamental","pubTime":"2026-02-05 20:44","pubTimestamp":1770295476,"startTime":"0","endTime":"0","summary":"Qyuns Therapeutics Co., Ltd. (Stock Code: 2509) announced that a total of 2,487,800 ordinary shares were repurchased on The Stock Exchange of Hong Kong Limited between November 6, 2025, and the date...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.qyuns.net","stockEarnings":[{"period":"1week","weight":-0.1206},{"period":"1month","weight":0},{"period":"3month","weight":-0.1754},{"period":"6month","weight":-0.2433},{"period":"1year","weight":0.7023},{"period":"ytd","weight":-0.041}],"compareEarnings":[{"period":"1week","weight":-0.007},{"period":"1month","weight":0.0253},{"period":"3month","weight":-0.0288},{"period":"6month","weight":-0.007},{"period":"1year","weight":0.1857},{"period":"ytd","weight":0.0136}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Qyuns Therapeutics Co Ltd is a China-based company mainly engaged in biopharmaceuticals. The Company is mainly engaged in biotechnology research and development of biological therapies for autoimmune and allergic diseases. The Company's business mainly covers four major disease areas, including skin, rheumatism, respiratory and digestive tract diseases. The Company is developing eight projects, with target indications including psoriasis, atopic dermatitis, rheumatoid arthritis, inflammatory bowel disease and asthma. The Company's core products include QX002N and QX005N.","exchange":"SEHK","name":"QYUNS-B","nameEN":"QYUNS-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"QYUNS-B(02509),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest QYUNS-B(02509) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"QYUNS-B,02509,QYUNS-B股票,QYUNS-B股票老虎,QYUNS-B股票老虎国际,QYUNS-B行情,QYUNS-B股票行情,QYUNS-B股价,QYUNS-B股市,QYUNS-B股票价格,QYUNS-B股票交易,QYUNS-B股票购买,QYUNS-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"QYUNS-B(02509),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest QYUNS-B(02509) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}